Table 3.
Model-estimated overall survival and mean costs for advanced lung cancer subpopulations. Outcomes represent patients who receive at least one line of therapy
| Overall survival | Mean costa (2020 AUD) | |||||
|---|---|---|---|---|---|---|
| Mean (months)a | 1 year (%) | 2 years (%) | 5 years (%) | 10 years (%) | ||
| ALK+ (NSCC) | 65.0 | 84 | 71 | 49 | 33 | $529,005 |
| EGFR+ (NSCC) | 39.0 | 82 | 57 | 21 | 6 | $330,341 |
| High PD-L1 (NSCC) | 28.8 | 70 | 43 | 12 | 3 | $198,669 |
| High PD-L1 (SCC) | 24.8 | 66 | 33 | 8 | 3 | $172,129 |
| Low PD-L1 (NSCC) | 23.3 | 64 | 33 | 7 | 1 | $177,607 |
| Low PD-L1 (SCC) | 21.4 | 65 | 31 | 4 | 1 | $169,108 |
| Other/NOS | 22.7 | 63 | 32 | 6 | 1 | $179,418 |
| ROS1+ (NSCC) | 43.8 | 78 | 58 | 27 | 12 | $323,826 |
| SCLC | 14.4 | 46 | 14 | 1 | 0 | $122,867 |
ALK anaplastic lymphoma kinase, AUD Australian dollars, EGFR epidermal growth factor receptor, NSCC non-squamous cell carcinoma, Other/NOS other-specified or not-otherwise-specified, PD-L1 programmed death ligand 1, ROS1 c-ros oncogene 1, SCC squamous cell carcinoma, SCLC small-cell lung cancer
aEstimated up to 10 years after diagnosis